Literature DB >> 3697960

Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines.

S A Metcalfe, K Cain, B T Hill.   

Abstract

Two human prostate tumor cell lines which exhibit a 2.4-fold difference in sensitivity to cis-platinum (cis-Pt) were found to possess slightly different sulphydryl contents, and the presence of a metallothionein-like zinc-binding protein was demonstrated in the line exhibiting relative resistance to cis-Pt. Although these factors have been postulated to play a role in the mechanism(s) of resistance to cis-Pt in other cell types, preliminary data in this report suggest that differences found in drug uptake and subsequent binding to DNA are most likely responsible for variations in cis-Pt sensitivity displayed by these prostate tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3697960     DOI: 10.1016/0304-3835(86)90007-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

Review 1.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 2.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Authors:  Brian G Blair; Christopher A Larson; Preston L Adams; Paolo B Abada; Catherine E Pesce; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-10-07       Impact factor: 4.436

4.  Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1- cyclobutanedicarboxylato(2-)](2 methyl-1,4-butane-diamine-N,N')platinum.

Authors:  A J Kraker; C W Moore; B J Roberts; W R Leopold; W L Elliott
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

5.  Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Authors:  Brian G Blair; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

6.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

Authors:  S Y Loh; P Mistry; L R Kelland; G Abel; K R Harrap
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.